James Peyer, Founder @ Cambrian
In this episode, Jack Richardson and Richard Armstrong engage with James Pyre to explore the biotech landscape, delving into his background and the founding of Cambrian. The discussion highlights Cambrian's mission to tackle aging biology and compares biotech to tech investment landscapes. James shares insights into Cambrian's early funding, metabolism research, and drug development efforts. The conversation navigates the complexities of the regulatory environment and data management, emphasizing strategies to accelerate drug development and the future of longevity drugs. The episode wraps up with a quick-fire round of questions with James Pyre, followed by closing remarks.
Key Points
- Cambrian's mission includes developing therapeutics that restore pathways degraded by aging to treat and prevent diseases like cancer and heart disease.
- James Pyre's personal experience with his grandfather's cancer was a driving force behind his pursuit of biotech innovations aimed at preventing age-related diseases.
- The regulatory landscape for biotech is complex, but Cambrian's strategic approach involves targeting specific diseases first, then expanding drug applications to broader preventative health uses.
James Peyer is the CEO and founder of Cambrian Bio, a company that develops therapeutics targeting key biological pathways that decline or malfunction with age to create medicines that have the potential to treat and prevent some of today's most debilitating diseases.
Cambrian is viewed as one of the most exciting biotech companies around, raising $160m in the last 5 years.
Brought to you by TAV, James joins Jack and Rich to discuss his personal journey, longevity, Cambrian's journey to human trials, regulatory considerations and so much more.
Chapters
| 0:00 | |
| 3:16 | |
| 10:10 | |
| 12:29 | |
| 18:00 | |
| 24:11 | |
| 29:42 | |
| 34:25 | |
| 37:41 |
Transcript
Loading transcript...